Press "Enter" to skip to content

Patent delisted for Astrazeneca Ab drug BYDUREON

0
Copyright © DrugPatentWatch. Originally published at Patent delisted for Astrazeneca Ab drug BYDUREON

Annual Drug Patent Expirations for BYDUREON
Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug.

BYDUREON drug price trends.

Drug patent litigation for BYDUREON.

This drug has four hundred and thirty-six patent family members in forty-eight countries.

The generic ingredient in BYDUREON is exenatide. One supplier is listed for this compound. Additional details are available on the exenatide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Astrazeneca Ab drug BYDUREON
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions